vs
Amphastar Pharmaceuticals, Inc.（AMPH）とVia Renewables, Inc.（VIASP）の財務データ比較。上の社名をクリックして会社を切り替えられます
Amphastar Pharmaceuticals, Inc.の直近四半期売上が大きい（$183.1M vs $127.8M、Via Renewables, Inc.の約1.4倍）。Amphastar Pharmaceuticals, Inc.の純利益率が高く（13.3% vs 5.4%、差は8.0%）。Via Renewables, Inc.の前年同期比売上増加率が高い（22.5% vs -1.8%）。Amphastar Pharmaceuticals, Inc.の直近四半期フリーキャッシュフローが多い（$24.6M vs $-4.8M）。過去8四半期でVia Renewables, Inc.の売上複合成長率が高い（5.9% vs 3.2%）
Amphastar Pharmaceuticalsは上場されている米国の特殊製薬企業です。2004年5月に設立され、主に吸入剤および鼻腔内投与製品の開発、生産、販売を行っており、特色ある医薬品分野で事業を展開しています。
EDFパワーソリューションズはフランスの公益事業者であるEDFグループの完全子会社で、再生可能エネルギー発電事業を専門としています。統合オペレーターとして同グループは再生可能エネルギー施設の開発・建設融資を行い、自社および第三者向けに運用・保守業務を提供しています。
AMPH vs VIASP — 直接比較
損益計算書 — Q4 FY2025 vs Q4 FY2025
| 指標 | | |
|---|---|---|
| 売上 | $183.1M | $127.8M |
| 純利益 | $24.4M | $6.9M |
| 粗利率 | 46.8% | 34.4% |
| 営業利益率 | 19.4% | 15.2% |
| 純利益率 | 13.3% | 5.4% |
| 売上前年比 | -1.8% | 22.5% |
| 純利益前年比 | -35.7% | -30.9% |
| EPS（希薄化後） | $0.51 | $1.19 |
緑 = その指標でリード。会計年度がずれている場合は期間が異なる場合あり
8四半期 売上・利益トレンド
並べて比較する四半期履歴。決算期がずれていても暦四半期で整列
| Q4 25 | $183.1M | $127.8M | ||
| Q3 25 | $191.8M | $103.3M | ||
| Q2 25 | $174.4M | $90.0M | ||
| Q1 25 | $170.5M | $142.3M | ||
| Q4 24 | $186.5M | $104.3M | ||
| Q3 24 | $191.2M | $93.8M | ||
| Q2 24 | $182.4M | $86.7M | ||
| Q1 24 | $171.8M | $114.1M |
| Q4 25 | $24.4M | $6.9M | ||
| Q3 25 | $17.4M | $757.0K | ||
| Q2 25 | $31.0M | $2.7M | ||
| Q1 25 | $25.3M | $8.8M | ||
| Q4 24 | $38.0M | $9.9M | ||
| Q3 24 | $40.4M | $2.1M | ||
| Q2 24 | $37.9M | $7.6M | ||
| Q1 24 | $43.2M | $8.6M |
| Q4 25 | 46.8% | 34.4% | ||
| Q3 25 | 51.4% | 23.1% | ||
| Q2 25 | 49.6% | 30.0% | ||
| Q1 25 | 50.0% | 32.9% | ||
| Q4 24 | 46.5% | 51.9% | ||
| Q3 24 | 53.3% | 26.8% | ||
| Q2 24 | 52.2% | 50.4% | ||
| Q1 24 | 52.4% | 39.5% |
| Q4 25 | 19.4% | 15.2% | ||
| Q3 25 | 13.2% | 3.1% | ||
| Q2 25 | 24.2% | 6.7% | ||
| Q1 25 | 21.9% | 17.5% | ||
| Q4 24 | 24.2% | 31.5% | ||
| Q3 24 | 29.8% | 5.3% | ||
| Q2 24 | 30.3% | 23.8% | ||
| Q1 24 | 27.9% | 22.6% |
| Q4 25 | 13.3% | 5.4% | ||
| Q3 25 | 9.0% | 0.7% | ||
| Q2 25 | 17.8% | 3.0% | ||
| Q1 25 | 14.8% | 6.2% | ||
| Q4 24 | 20.4% | 9.5% | ||
| Q3 24 | 21.1% | 2.3% | ||
| Q2 24 | 20.8% | 8.8% | ||
| Q1 24 | 25.1% | 7.5% |
| Q4 25 | $0.51 | $1.19 | ||
| Q3 25 | $0.37 | $-0.41 | ||
| Q2 25 | $0.64 | $0.09 | ||
| Q1 25 | $0.51 | $1.83 | ||
| Q4 24 | $0.74 | $2.33 | ||
| Q3 24 | $0.78 | $-0.17 | ||
| Q2 24 | $0.73 | $1.51 | ||
| Q1 24 | $0.81 | $1.81 |
貸借対照表と財務力
直近四半期の流動性・レバレッジ・純資産のスナップショット
| 指標 | | |
|---|---|---|
| 現金・短期投資手元流動性 | $282.8M | $41.8M |
| 総負債低いほど良い | $608.7M | $120.0M |
| 株主資本純資産 | $788.8M | $67.7M |
| 総資産 | $1.6B | $331.3M |
| 負債/資本比率低いほどレバレッジが低い | 0.77× | 1.77× |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $282.8M | $41.8M | ||
| Q3 25 | $276.2M | $53.6M | ||
| Q2 25 | $231.8M | $62.1M | ||
| Q1 25 | $236.9M | $64.7M | ||
| Q4 24 | $221.6M | $53.1M | ||
| Q3 24 | $250.5M | $66.6M | ||
| Q2 24 | $217.8M | $53.6M | ||
| Q1 24 | $289.6M | $50.4M |
| Q4 25 | $608.7M | $120.0M | ||
| Q3 25 | $608.6M | $105.0M | ||
| Q2 25 | $607.7M | $100.0M | ||
| Q1 25 | $603.9M | $101.0M | ||
| Q4 24 | $601.6M | $106.0M | ||
| Q3 24 | $596.4M | $89.0M | ||
| Q2 24 | $586.9M | $93.0M | ||
| Q1 24 | $594.0M | $91.0M |
| Q4 25 | $788.8M | $67.7M | ||
| Q3 25 | $776.7M | $63.7M | ||
| Q2 25 | $757.5M | $68.2M | ||
| Q1 25 | $751.3M | $72.7M | ||
| Q4 24 | $732.3M | $66.7M | ||
| Q3 24 | $727.7M | $58.2M | ||
| Q2 24 | $713.3M | $58.3M | ||
| Q1 24 | $672.4M | $53.2M |
| Q4 25 | $1.6B | $331.3M | ||
| Q3 25 | $1.7B | $304.8M | ||
| Q2 25 | $1.6B | $316.3M | ||
| Q1 25 | $1.6B | $347.4M | ||
| Q4 24 | $1.6B | $344.9M | ||
| Q3 24 | $1.5B | $298.4M | ||
| Q2 24 | $1.5B | $299.7M | ||
| Q1 24 | $1.6B | $302.7M |
| Q4 25 | 0.77× | 1.77× | ||
| Q3 25 | 0.78× | 1.65× | ||
| Q2 25 | 0.80× | 1.47× | ||
| Q1 25 | 0.80× | 1.39× | ||
| Q4 24 | 0.82× | 1.59× | ||
| Q3 24 | 0.82× | 1.53× | ||
| Q2 24 | 0.82× | 1.60× | ||
| Q1 24 | 0.88× | 1.71× |
キャッシュフローと資本効率
再投資後に実際に生み出すキャッシュ。純利益より操作が難しい
| 指標 | | |
|---|---|---|
| 営業キャッシュフロー直近四半期 | $32.9M | $-4.2M |
| フリーキャッシュフロー営業CF - 設備投資 | $24.6M | $-4.8M |
| FCFマージンFCF / 売上 | 13.4% | -3.7% |
| 設備投資強度設備投資 / 売上 | 4.5% | 0.4% |
| キャッシュ転換率営業CF / 純利益 | 1.35× | -0.61× |
| 直近12ヶ月FCF直近4四半期 | $121.2M | $39.1M |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $32.9M | $-4.2M | ||
| Q3 25 | $52.6M | $2.4M | ||
| Q2 25 | $35.6M | $19.0M | ||
| Q1 25 | $35.1M | $24.9M | ||
| Q4 24 | $29.0M | $2.0M | ||
| Q3 24 | $60.0M | $20.1M | ||
| Q2 24 | $69.1M | $11.2M | ||
| Q1 24 | $55.3M | $17.1M |
| Q4 25 | $24.6M | $-4.8M | ||
| Q3 25 | $47.2M | $1.9M | ||
| Q2 25 | $25.0M | $18.4M | ||
| Q1 25 | $24.4M | $23.5M | ||
| Q4 24 | $16.6M | $1.6M | ||
| Q3 24 | $46.2M | $19.7M | ||
| Q2 24 | $63.1M | $10.9M | ||
| Q1 24 | $46.5M | $16.6M |
| Q4 25 | 13.4% | -3.7% | ||
| Q3 25 | 24.6% | 1.9% | ||
| Q2 25 | 14.3% | 20.5% | ||
| Q1 25 | 14.3% | 16.5% | ||
| Q4 24 | 8.9% | 1.5% | ||
| Q3 24 | 24.1% | 21.0% | ||
| Q2 24 | 34.6% | 12.6% | ||
| Q1 24 | 27.1% | 14.6% |
| Q4 25 | 4.5% | 0.4% | ||
| Q3 25 | 2.8% | 0.4% | ||
| Q2 25 | 6.1% | 0.6% | ||
| Q1 25 | 6.3% | 1.0% | ||
| Q4 24 | 6.7% | 0.4% | ||
| Q3 24 | 7.2% | 0.4% | ||
| Q2 24 | 3.3% | 0.3% | ||
| Q1 24 | 5.1% | 0.4% |
| Q4 25 | 1.35× | -0.61× | ||
| Q3 25 | 3.03× | 3.12× | ||
| Q2 25 | 1.15× | 6.94× | ||
| Q1 25 | 1.39× | 2.84× | ||
| Q4 24 | 0.76× | 0.20× | ||
| Q3 24 | 1.48× | 9.41× | ||
| Q2 24 | 1.82× | 1.47× | ||
| Q1 24 | 1.28× | 2.00× |
財務フロー比較
売上 → 粗利 → 営業利益 → 純利益のサンキー図
セグメント別売上内訳
AMPH
| Other Products | $62.4M | 34% |
| Baqsimi | $46.7M | 26% |
| Primatenemist | $27.9M | 15% |
| Epinephrine | $17.1M | 9% |
| Lidocaine | $14.9M | 8% |
| Glucagon | $14.1M | 8% |
VIASP
| Retail Electricity | $79.7M | 62% |
| Retail Natural Gas | $48.9M | 38% |
